comparemela.com

Latest Breaking News On - Clinical trials amp medical discoveries - Page 5 : comparemela.com

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

/PRNewswire/ Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced.

United statesLennonh ventilatoryChristian heidbrederHealth statisticsWiley online libraryNational centerPrnewswire indiviorClinical pharmacologyInduced respiratory depressionHealthy volunteersIntranasal nalmefeneIntranasal naloxoneOnline libraryChief scientific officerRecurrent respiratoryCentral nervous system depression

New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat.

United statesJonathan grahamMichael meoMarlena abdinoorSloan simpsonAngelika jahreisR sharon chinthrajahAmerica julie masowPrnewswire novartisParag mahantiRobert woodEudowood division of allergyJohns hopkins children centerNational institute of allergyAsthma researchGenentech inc

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today.

United statesLisa guitermanStacy lindborgChaim lebovitsPrnewswire brainstorm cell therapeutics incBrainstorm cell therapeutics incEuropean medicines agencyCalifornia institute for regenerative medicineNational ms societyDrug administrationStorm cell therapeuticsSpecial protocol assessmentChief executive officerProtocol assessmentFloor effectOrphan drug

Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer s Disease

/PRNewswire/ Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of.

Kyonggi doSouth koreaJanssen pharmaSeungyong yoonKyung hoon hwangTaeyoung yoonUniversity of ulsan college medicineYuhan corpAsan medical centerPrnewswire oscotec incOscotec incMild cognitive impairmentClinical investigationUlsan collegeHoon hwangOscotec inc

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with.

District of columbiaUnited statesUnited kingdomPercy carterBecker hewesExchange commissionEuropean commissionDrug administrationConvention centerPrnewswire blueprint medicines corporation nasdaqAmerican academy of allergyMedicines corporationAnnual meetingChief medical officerBlueprint medicinesDurable symptom impact

vimarsana © 2020. All Rights Reserved.